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Christopher D. Buckley1* and Harris Perlman2*Rheumatology is at a very exciting stage in its long and
illustrious history. New biological therapies have revolu-
tionized the treatment of immune-mediated inflamma-
tory diseases. The genetic, epigenetic and environmental
mechanisms that drive musculoskeletal diseases are giving
up their secrets, and patients are much more involved in
the decisions that matter to them… “nothing about us
without us”. These rapid advances in musculoskeletal
medicine suggest that finally Cinderella has come to
the ball!
Musculoskeletal medicine is a broad field, which en-
compasses many clinical and scientific disciplines that
are already served by excellent journals. So what is
unique about Arthritis Research & Therapy (AR&T) and
whom is the journal aimed at?
In its first decade, AR&T under the guidance of its
founding Editors has established itself as a leading jour-
nal for the community of researchers and clinicians in-
terested in the science of musculoskeletal medicine. It is
open access, links basic science with clinical advances
and enjoys independence and a freedom to be innova-
tive; for example, it was the first open-access journal in
the field. We believe that this is key for our continued
growth.
What will be our editorial focus as we work with our
illustrious editorial team to steer the journal as it enters
its second decade? Our goal is to ensure that the journal
serves and is served by a loyal and engaged scientific
and clinical community. That is why we have followed
our founders’ policy of having two Editors-in-Chief: one
a clinician, the other a scientist. We also believe that,
more than ever before, the best developments and dis-
coveries occur through collaborations across various* Correspondence: c.d.buckley@bham.ac.uk; h-perlman@northwestern.edu
1Rheumatology Research Group, Institute for Translational Inflammation
Research, College of Medical and Dental Sciences, University of Birmingham
Research Laboratories, Queen Elizabeth Hospital Birmingham, Birmingham,
B15 2WD, UK
2Department of Medicine, Division of Rheumatology, Feinberg School of
Medicine, Northwestern University, 240 E. Huron Street, McGaw M338,
Chicago, IL 60611, USA
© 2015 Buckley and Perlman. Open Access T
4.0 International License (http://creativecomm
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeacademic centres worldwide. This is why our two Editors
are from different continents and our Section Editors
are from all over the world. We will continue to seek
out genuine translational science that has delivered such
stunning advances and at the same time we will adapt to
changes in the scientific landscape. To achieve this, we
have set ourselves the following objectives.
Firstly, we will continue to expand the remit of the
journal to include other rheumatic diseases such as
osteoarthritis, crystal arthritis, lupus and the connective
tissue diseases. Although AR&T has traditionally focused
on translational research, it has not published many piv-
otal clinical trials. Therefore, we will try to publish the
best clinical trials and outcome studies, including those
that report on health economic evaluation.
Secondly, we aim to continue to publish research of
the highest quality related to basic biological processes.
We will accomplish this by attracting manuscripts that
report the use of cutting-edge technologies that link
clinical and radiologic phenotypes with genomic, tran-
scriptomic, epigenomic and proteomic measurements in
clinical samples from patients with musculoskeletal dis-
ease, thereby generating new insights and hypotheses
about disease pathogenesis.
Thirdly, we will reinvigorate our reviewer base by pro-
moting the role of junior faculty and, in particular, post-
doctoral fellow researchers. These young investigators
represent the future of our specialty and need our en-
couragement and support as they work to generate in-
sights and therapies for the future. We would like these
young members of the journal to become the new back-
bone of our review process. We will also highlight the
research of junior fellows by using podcasts. This junior
generation are our future and they deserve attention in
promoting their outstanding work. They are very com-
petent and comfortable with new technologies yet often
feel undervalued and under-represented.
Fourthly, we will work with specialty societies to high-
light novel ongoing research at their meetings in an aim
to expand the research scope and reportage of the journal.his article is distributed under the terms of the Creative Commons Attribution
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cutting-edge areas of rheumatic disease that are pub-
lished in our journal as well as others.
So how will we achieve these goals? We have established
a new editorial structure with an international selection of
outstanding and expert investigators. These new Section
Editors will oversee six general research themes: David
Pisetsky (USA) – Immunology and Pathology; Maya Buch
(UK) – Pharmacology and Therapeutics; Laure Gossec
(France) – Epidemiology and Clinical Trials; Edward
Schwarz (USA) – Outcomes and Imaging; Kazuhiko
Yamamoto (Japan) – Genetics and Epigenetics; and
Thomas Pap (Germany) – Bone and Cartilage Biology.
We have moved over to an easy-to-use online editorial
management system that will improve our governance
and editorial consistency and enhance the turnaround
rate for manuscripts. It will also allow us to monitor the
review process and tell us whether we are accomplishing
what we said we would. We have refreshed and will con-
tinue to revise our pool of Associate Editors and Board
Members so that we have more involvement from junior
faculty. We are also fully aware that reviewer fatigue is a
problem throughout academia. Therefore, our Associate
Editors and Board Members will commit to reviewing at
least six manuscripts a year. They will also act as our
advocates for the journal to the scientific, clinical and
patient populations that we serve.
Our ultimate aim is to be not only a trusted, inter-
nationally respected rheumatic disease journal but one
that expands the boundaries of musculoskeletal disease
research and identifies with an empowered scientific and
clinical community. Thus, although impact factors do
matter, we are not obsessed by them. We believe that by
engaging with our research community we will attract
the best research that will ultimately lead to an increased
impact factor and enhance our international recognition.
As the new Editors we invite you to join us in this new
mission for AR&T.
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